

Cover Story
After a courtroom victory against Amgen Inc. this summer, the last of the obstacles was removed for the first biosimilar agent—a white blood cell growth factor—to enter the U.S. market.
By Matthew Bin Han Ong
By Matthew Bin Han Ong
In Brief
Drugs & Targets


Trending Stories
- Christine Lovly to lead City of Hope’s new national thoracic oncology program
- FDA to remove black box warnings on hormone therapy for menopause
Trump-era “gold standard science” is not to be confused with gold standard of scientific evidence - Montefiore Einstein Director Edward Chu dies of glioblastoma at 66
- Rick Pazdur’s CDER appointment comes at exactly the right moment for FDA
- Smoldering multiple myeloma: Rethinking the waiting game
- Richard Pazdur, a respected insider with a plan to reengineer FDA, steps in as CDER director











